Akebia Therapeutics, Inc. 8-K

What Happened
Akebia Therapeutics, Inc. (AKBA) and U.S. Renal Care (USRC) announced on June 30, 2026 (press release furnished as Exhibit 99.1 to the 8‑K) that a planned interim analysis of the VOICE trial met predefined stopping criteria. The trial sponsor, USRC Kidney Research, stopped the randomized, open‑label, active‑controlled non‑inferiority VOICE trial following a recommendation from the Independent Data Monitoring Committee and Trial Steering Committee based on data through the June 1, 2026 cutoff.

Key Details

• VOICE enrolled 2,116 patients to compare Vafseo® (vadadustat) three times weekly vs standard‑of‑care erythropoiesis‑stimulating agents (ESAs).
• Primary composite endpoint (hierarchical: all‑cause mortality and all‑cause hospitalization) met stopping criteria with a win odds of 1.16 (95% CI 1.06–1.28; p = 0.0016), establishing non‑inferiority and superiority.
• Hospitalizations: 1.11 vs 1.23 hospitalizations per patient‑year (Vafseo vs ESA); incidence rate ratio 0.90 (95% CI 0.824–0.988), a statistically significant reduction.
• Mortality: no significant difference — 8.77% vs 8.78% per 100 patient‑years (incidence rate ratio 1.00; 95% CI 0.718–1.391).
• Vafseo (vadadustat) is an oral HIF‑prolyl hydroxylase inhibitor approved for anemia in adults with chronic kidney disease receiving dialysis ≥3 months.

Why It Matters
The interim result is material because the trial met prespecified rules for stopping early due to both non‑inferiority and statistical superiority on the primary composite endpoint, and the sponsor halted the study. For investors, the data show a statistically significant reduction in hospitalizations with Vafseo versus ESAs while mortality was similar between groups. Akebia and USRC disclosures around next steps (regulatory, commercial implications, and any additional analyses) and any financial impact will be important to monitor in forthcoming company communications.